Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of apremilast in DMARD-naive active psoriatic arthritis
2010-020324-22Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apremilast in psoriatic arthritis (PsA) (3 arms), sponsored by Celgene Corporation. Primary endpoint: ACR20 response at Week 16. Started Dec 2010; status: completed.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2010-020324-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020324-22.